


**APLASTIC ANEMIA & MDS
INTERNATIONAL FOUNDATION, INC.**

AUDITED FINANCIAL STATEMENTS

For the years ended December 31, 2022 and 2021



AA • MDS

INTERNATIONAL FOUNDATION

Aplastic Anemia & MDS International Foundation, Inc.

TABLE OF CONTENTS

	Page
Independent Auditor's Report	1-2
Financial Statements	
Statements of Financial Position	3
Statements of Activities	4
Statements of Functional Expenses	5-6
Statements of Cash Flows	7
Notes to the Financial Statements	8-21

INDEPENDENT AUDITOR'S REPORT

Board of Directors
Aplastic Anemia & MDS International Foundation, Inc.
Bethesda, Maryland

We have audited the accompanying financial statements of Aplastic Anemia & MDS International Foundation, Inc. (a nonprofit organization), which comprise the statements of financial position as of December 31, 2022 and 2021, and the related statements of activities, functional expenses, and cash flows for the years then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Aplastic Anemia & MDS International Foundation, Inc. as of December 31, 2022 and 2021, and the related statements of activities, functional expenses, and cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of Aplastic Anemia & MDS International Foundation, Inc. (the Foundation) and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Changes in Accounting Principles

As discussed in Note 1, the Foundation adopted the requirements of Financial Accounting Standards Board's Accounting Standards Update No 2016-02, *Leases* (Topic 842). Our opinion is not modified with respect to this adoption.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Foundation's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Foundation's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

UHY LLP

Columbia, Maryland
June 2, 2023

APLASTIC ANEMIA & MDS INTERNATIONAL FOUNDATION, INC.
STATEMENTS OF FINANCIAL POSITION
December 31, 2022 and 2021

	<u>2022</u>	<u>2021</u>
ASSETS		
CURRENT ASSETS		
Cash and cash equivalents	\$ 2,938,625	\$ 2,774,248
Contributions and grants receivable	686,175	367,344
Prepaid expenses	33,078	23,250
Investments	<u>1,420,329</u>	<u>1,613,778</u>
Total current assets	<u>5,078,207</u>	<u>4,778,620</u>
NON-CURRENT ASSETS		
Property and equipment		
Furniture, equipment and website	538,534	487,291
Less: accumulated depreciation	<u>(467,020)</u>	<u>(436,405)</u>
Total property and equipment, net	71,514	50,886
Security deposits	14,642	14,922
Right-of-use asset - operating, net	242,729	-
Charitable Remainder Trust	<u>376,244</u>	<u>354,948</u>
Total non-current assets	<u>705,129</u>	<u>420,756</u>
Total assets	<u>\$ 5,783,336</u>	<u>\$ 5,199,376</u>
LIABILITIES AND NET ASSETS		
CURRENT LIABILITIES		
Accounts payable	\$ 30,950	\$ 45,658
Accrued expenses	38,487	116,833
Deferred rent	-	22,253
Lease liability - operating	<u>181,144</u>	<u>-</u>
Total current liabilities	<u>250,581</u>	<u>184,744</u>
NON-CURRENT LIABILITIES		
Deferred rent, net of current portion	-	39,990
Lease liability - operating, net of current portion	<u>101,575</u>	<u>-</u>
Total non-current liabilities	<u>101,575</u>	<u>39,990</u>
Total liabilities	<u>352,156</u>	<u>224,734</u>
NET ASSETS		
Without donor restrictions:		
Available for operations	4,357,451	3,616,727
Board-designated	<u>90,000</u>	<u>150,000</u>
Total net assets without donor restrictions	4,447,451	3,766,727
With donor restrictions	<u>983,729</u>	<u>1,207,915</u>
Total net assets	<u>5,431,180</u>	<u>4,974,642</u>
Total liabilities and net assets	<u>\$ 5,783,336</u>	<u>\$ 5,199,376</u>

See notes to financial statements.

APLASTIC ANEMIA & MDS INTERNATIONAL FOUNDATION, INC.
STATEMENTS OF ACTIVITIES
For the years ended December 31, 2022 and 2021

	2022			2021		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
SUPPORT AND REVENUE						
Contributions and grants:						
Individuals	\$ 399,471	\$ 145,625	\$ 545,096	\$ 550,557	\$ 123,024	\$ 673,581
Corporations and other	193,997	1,838,312	2,032,309	169,487	2,213,958	2,383,445
Foundations	104,961	30,000	134,961	57,496	15,000	72,496
Contributed goods, services and securities	12,577	14,000	26,577	3,595	21,600	25,195
Paycheck Protection Program grant	-	-	-	-	182,336	182,336
Wills and change in present value of trust	442,923	21,296	464,219	37,025	20,092	57,117
Events	26,342	-	26,342	24,315	-	24,315
Investment returns, net	(173,020)	-	(173,020)	112,993	-	112,993
Net assets released from restrictions	2,273,419	(2,273,419)	-	2,366,186	(2,366,186)	-
Total support and revenue	3,280,670	(224,186)	3,056,484	3,321,654	209,824	3,531,478
EXPENSES						
Program services	2,084,363	-	2,084,363	1,685,770	-	1,685,770
General and administrative	237,380	-	237,380	197,487	-	197,487
Fundraising	278,203	-	278,203	236,646	-	236,646
Total expenses	2,599,946	-	2,599,946	2,119,903	-	2,119,903
Change in Net Assets	680,724	(224,186)	456,538	1,201,751	209,824	1,411,575
Net Assets, Beginning	3,766,727	1,207,915	4,974,642	2,564,976	998,091	3,563,067
Net Assets, Ending	\$ 4,447,451	\$ 983,729	\$ 5,431,180	\$ 3,766,727	\$ 1,207,915	\$ 4,974,642

See notes to financial statements.

APLASTIC ANEMIA & MDS INTERNATIONAL FOUNDATION, INC.
STATEMENT OF FUNCTIONAL EXPENSES
For the year ended December 31, 2022

	2022			
	Program Services	General and Administrative	Fundraising	Total Expenses
Personnel costs:				
Salaries	\$ 709,136	\$ 53,991	\$ 113,296	\$ 876,423
Employee benefits	66,649	5,075	10,648	82,372
Payroll taxes	51,707	3,937	8,261	63,905
Total personnel costs	827,492	63,003	132,205	1,022,700
Professional and contract services	587,066	44,709	46,560	678,335
Office expenses	78,104	9,367	53,338	140,809
Information technology	76,584	28,975	9,265	114,824
Occupancy and related expenses	120,994	51,064	16,145	188,203
Travel and meetings	118,032	2,260	8,650	128,942
Professional development	51,570	21,771	6,908	80,249
Awards, grants and honoraria	186,073	-	-	186,073
Insurance	13,472	5,687	1,798	20,957
Bank service fees	5,296	2,236	707	8,239
Depreciation	19,680	8,308	2,627	30,615
 Total expenses	 \$ 2,084,363	 \$ 237,380	 \$ 278,203	 \$ 2,599,946

APLASTIC ANEMIA & MDS INTERNATIONAL FOUNDATION, INC.
STATEMENT OF FUNCTIONAL EXPENSES
For the year ended December 31, 2021

	2021			
	Program Services	General and Administrative	Fundraising	Total Expenses
Personnel costs:				
Salaries	\$ 726,282	\$ 25,716	\$ 59,319	\$ 811,317
Employee benefits	70,453	2,494	5,754	78,701
Payroll taxes	59,267	2,098	4,841	66,206
Total personnel costs	856,002	30,308	69,914	956,224
Professional and contract services	368,012	46,513	88,789	503,314
Office expenses	30,121	9,782	34,460	74,363
Information technology	96,150	40,332	12,490	148,972
Occupancy and related expenses	111,695	51,538	15,679	178,912
Travel and meetings	47,130	272	8,978	56,380
Professional development	1,235	432	131	1,798
Awards, grants and honoraria	135,743	-	636	136,379
Insurance	12,335	5,691	1,731	19,757
Bank service fees	6,174	2,849	866	9,889
Depreciation	21,173	9,770	2,972	33,915
Total expenses	<u>\$ 1,685,770</u>	<u>\$ 197,487</u>	<u>\$ 236,646</u>	<u>\$ 2,119,903</u>

APLASTIC ANEMIA & MDS INTERNATIONAL FOUNDATION, INC.
STATEMENTS OF CASH FLOWS
For the years ended December 31, 2022 and 2021

	<u>2022</u>	<u>2021</u>
Cash flows from operating activities		
Change in net assets	\$ 456,538	\$ 1,411,575
Adjustments to reconcile change in net assets to net cash and cash equivalents provided by operating activities:		
Non-cash activities:		
Depreciation	30,615	33,915
Amortization of right-of-use asset - operating	168,884	-
Net unrealized (gains) losses on investments	193,251	(51,322)
Realized (gains) losses on investments	12,232	(25,673)
Donated investment securities	(7,929)	(3,293)
Increase in fair value of Charitable Remainder Trust	(21,296)	(20,092)
Decrease (increase) in assets:		
Contributions and grants receivable	(318,831)	1,430,619
Prepaid expenses	(9,828)	64,168
Security deposits	280	-
Increase (decrease) in liabilities:		
Accounts payable	(14,708)	(1,074)
Accrued expenses	(78,346)	(751,845)
Deferred rent	-	(41,890)
Payments on lease liability - operating	(191,137)	-
Net cash provided by operating activities	<u>219,725</u>	<u>2,045,088</u>
Cash flows from investing activities		
Proceeds from sale of investments	886,493	1,233,000
Purchases of investments	(890,598)	(2,245,040)
Purchases of property and equipment	(51,243)	(14,198)
Net cash used in investing activities	<u>(55,348)</u>	<u>(1,026,238)</u>
Net increase in cash and cash equivalents	164,377	1,018,850
Cash and cash equivalents, beginning of year	<u>2,774,248</u>	<u>1,755,398</u>
Cash and cash equivalents, end of year	<u>\$ 2,938,625</u>	<u>\$ 2,774,248</u>

Supplemental Disclosures of Cash Flow Information

On January 1, 2022, a right-to-use asset - operating for office space in the amount of \$411,613 was recorded with an offset to lease liability - operating for \$473,856 and deferred rent of \$62,243 was eliminated under adoption of the new accounting policy for leases.

APLASTIC ANEMIA & MDS INTERNATIONAL FOUNDATION, INC.
NOTES TO THE FINANCIAL STATEMENTS
For the years ended December 31, 2022 and 2021

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GENERAL INFORMATION

Nature of the Organization

Aplastic Anemia & MDS International Foundation, Inc. (the Foundation) is a nonprofit organization, incorporated on December 6, 1983 in the State of Maryland and located in Bethesda, Maryland. The Foundation was formed to provide patient assistance, advocacy and support, to create and distribute educational materials and medical information, and to support research to find treatment for various bone marrow diseases, including Aplastic Anemia (AA), Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH), and related bone marrow failure diseases. The Foundation receives financial support from individual, corporate, foundation, Board contributions, and fundraising events, as well as income from investment sources and contributions from localized patient-support groups which fundraise independently of the Foundation.

The Foundation has allocated their resources among the following programs:

Patient programs - Educational conferences for patients and their caregivers, webinars, printed and electronic educational literature, disease-specific patient registries, and direct financial support for patient travel and medical expenses.

Professional programs - Research opportunities for healthcare professionals, professional conferences, access to disease-specific studies, and toolkits and other resources for healthcare professionals.

Awareness and outreach - The Foundation utilizes a number of platforms to increase awareness of Aplastic Anemia, MDS, PNH and other rare blood diseases, including social media, access to clinical trials on the website, printed and electronic patient guides, advocacy and other community outreach.

Supporting services at the Foundation include the following functional categories:

Management and general - Management and general expenses include those expenses for the overall operating and management of the Foundation, including accounting, office management, record keeping, and other centralized services and related administrative activities.

Fundraising activities and events - Fundraising includes publicizing and conducting fundraising campaigns, maintaining donor mailing lists, conducting special fundraising events, and other activities involved with soliciting contributions from individuals, foundations, corporations and others.

Basis of Accounting

The financial statements of the Foundation have been prepared on the accrual basis of accounting in conformity with accounting principles generally accepted in the United States of America (GAAP).

APLASTIC ANEMIA & MDS INTERNATIONAL FOUNDATION, INC.
NOTES TO THE FINANCIAL STATEMENTS
For the years ended December 31, 2022 and 2021

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GENERAL INFORMATION
(Continued)

Cash and Cash Equivalents

The Foundation considers all cash in its investment accounts and other highly liquid investments with initial maturities of three months or less to be cash equivalents. Cash equivalents are carried at cost, which approximates market value.

Investments

Investments are recorded at their readily determinable fair value. Interest, dividends, realized and unrealized gains and losses are included in investment income, net of investment expenses provided by external investment advisors, in the accompanying statements of activities.

Fair Value Measurements

The Foundation has adopted the provisions of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, *Fair Value Measurement*. FASB ASC 820 defines fair value, establishes a framework for measuring fair value, establishes a fair value hierarchy based on the quality of inputs (assumptions that market participants would use in pricing assets and liabilities, including assumptions about risk) used to measure fair value, and enhances disclosure requirements for fair value measurements. The Foundation accounts for a significant portion of its financial instruments at fair value or considers fair value in their measurement.

Contributions and Grants Receivable

Contributions and grants receivable that are expected to be collected in future years are recorded at their fair value, measured as the present value of their future cash flows. The discounts on these amounts are computed using risk-adjusted interest rates applicable to the years in which the promises are received. Amortization of the discounts is included in grants and contribution revenue. Conditional promises to give, those with a measurable barrier and right of return, are not included as support until the conditions are substantially met. All contributions and grants receivable are considered by management to be fully collectible and due within one year. Accordingly, an allowance for doubtful accounts or discount has not been established.

Property and Equipment

Fixed assets with acquisition costs of \$500 or more are stated at cost and depreciated using the straight-line method over the estimated useful lives of the related assets, generally three to seven years. The cost of maintenance and repairs is recorded as expenses are incurred. Depreciation expense for the years ended December 31, 2022 and 2021 totaled \$30,615 and \$33,915, respectively.

APLASTIC ANEMIA & MDS INTERNATIONAL FOUNDATION, INC.
NOTES TO THE FINANCIAL STATEMENTS
For the years ended December 31, 2022 and 2021

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GENERAL INFORMATION
(Continued)

Net Assets

Net assets, revenue, gains, and losses are classified based on the existence or absence of contributions with donor-imposed restrictions. Accordingly, net assets of the Foundation and changes therein are classified and reported as follows:

Net assets without donor restrictions - Net assets available for use in general operations and not subject to donor restrictions are recorded as net assets without donor restrictions. Assets restricted solely through the actions of the Board are referred to as Board-designated and are also reported as net assets without donor restrictions.

Net assets with donor restrictions - Donor-restricted contributions are reported as increases in net assets with donor restrictions, depending on the nature of the restrictions. If the restrictions expire (that is, when a stipulated time restriction ends or purpose restriction is accomplished) in the same reporting period in which the revenue is recognized, contributions restricted by donors are reported as increases in net assets without donor restrictions. When a restriction expires, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statements of activities as net assets released from donor restrictions. Gifts of long-lived assets and gifts of cash restricted for the acquisition of long-lived assets are recognized as revenue without donor restrictions when the assets are placed in service.

Some net assets with donor restrictions include a stipulation that assets provided be maintained permanently (perpetual in nature), while permitting the Foundation to expend the income generated by the assets in accordance with the provisions of additional donor-imposed stipulations or a Board-approved spending policy.

Revenue Recognition

The Foundation's support is received through contributions and grants from individuals and other entities. Contributions and grants are recognized in the appropriate category of net assets in the period received. The Foundation performs an analysis of the individual contribution and grant to determine if the revenue streams follow the contributions rules or if considered an exchange transaction depending on whether the transaction is reciprocal or nonreciprocal.

For contributions and grants qualifying under the contribution rules, support is recognized upon notification of the award and satisfaction of all conditions, if applicable. Conditional promises to give are not recognized until the condition on which they depend are substantially met. Unconditional contributions and grants that have donor restrictions are recognized as without donor restrictions only to the extent of actual expenses incurred in compliance with the donor-imposed restrictions and satisfaction of time restrictions; such funds in excess of expenses incurred are shown as net assets with donor restrictions in the accompanying financial statements.

APLASTIC ANEMIA & MDS INTERNATIONAL FOUNDATION, INC.
NOTES TO THE FINANCIAL STATEMENTS
For the years ended December 31, 2022 and 2021

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GENERAL INFORMATION
(Continued)

Revenue Recognition (continued)

Grant agreements classified as exchange transactions follow Accounting Standards Update (ASU) 2014-09, *Revenue from Contracts with Customers*, and revenue is recorded when the performance obligations are met. The revenue is recorded as without donor restrictions and the transaction price is based on expenses incurred in compliance with the criteria stipulated in the grant agreements.

Receivables from exchange transaction grants and contracts represent amounts due for reimbursable expenses incurred in accordance with the grant and contract agreements. Funding received in advance of incurring the related expenses is recorded as deferred revenue.

Contributed Goods, Services and Securities

Contributed goods, services and securities include t-shirts, hats, office supplies, presentation services (honoraria), and donated securities. Contributed goods and services are reflected as contributions at their fair value at the date of donation and are reported as unrestricted support unless explicit donor stipulations specify how donated assets must be used. The fair value of contributed presentation services is determined by the amount the Foundation offered as honoraria. Contributed securities are reported at the fair value on the date the securities are received.

Contributed goods and services are utilized by the Foundation's programs and supporting services. Contributed securities are sold as soon as the securities are received per the Foundation's investment and gifts policy.

The Foundation recognizes the fair value of contributed services received if such services either create or enhance nonfinancial assets or require specialized skills that are provided by individuals possessing those skills and would typically need to be purchased if not contributed. These amounts have been reported as contributed goods, services and securities on the statements of activities and included in professional contract services, information technology and awards, grants and honoraria expenses on the statements of functional expenses.

Volunteers contribute significant amounts of time to the Foundation's programs and fundraising campaigns; however, the financial statements do not reflect the value of these contributed services because they do not meet recognition criteria prescribed by generally accepted accounting principles.

Expense Allocation

The costs of providing the various programs and other activities have been summarized on a functional basis in the statements of activities and the statements of functional expenses. Expenses that can be identified with a specific program or supporting service are charged directly to that program or supporting service.

APLASTIC ANEMIA & MDS INTERNATIONAL FOUNDATION, INC.
NOTES TO THE FINANCIAL STATEMENTS
For the years ended December 31, 2022 and 2021

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GENERAL INFORMATION
(Continued)

Expense Allocation (Continued)

Supporting services are comprised of management and general and fundraising activities and events and include those costs that are not directly identifiable with any specific program but provide for the overall support and direction of the Foundation. The expenses that are allocated include occupancy, depreciation, insurance, technology and certain office expenses, which are allocated based on time and effort spent by the Foundation's personnel in such functions.

Use of Estimates

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Accordingly, actual results could differ from those estimates.

Tax Exempt Status and Income Tax Positions

The Foundation is exempt from federal and state income taxes (except taxes on unrelated business income) under Section 501(c)(3) of the Internal Revenue Code and is classified by the Internal Revenue Service as *other than a private foundation*. No provision for income taxes is required for the years ended December 31, 2022 and 2021 since the Foundation had no taxable income from unrelated business activities.

The income tax positions taken by the Foundation for any years open under the various statutes of limitations are that the Foundation continues to be exempt from income taxes and it has properly reported unrelated business income that is subject to income taxes. The Foundation believes that there are no tax positions taken or expected to be taken that would significantly increase unrecognized tax liabilities within 12 months of the reporting date. The Foundation evaluated its uncertainty in income taxes and determined that there were no matters that would require recognition in the financial statements or that may have any effect on its tax-exempt status. None of the Foundation's federal tax returns are currently under examination.

Adoption of New Accounting Standards for Leases

Effective January 1, 2022, the Foundation adopted the requirements of FASB ASC 842, *Leases*. This new standard establishes a right-of-use (ROU) model that requires a lessee to record an ROU asset and a lease liability on the statement of financial position for all leases with terms longer than 12 months. Leases are classified as finance leases when the Foundation expects to consume a major part of the economic benefits of the leased assets over the remaining lease term. Conversely, if the Foundation is not expected to consume a major part of the economic benefits of the leased assets, then they are classified as operating leases.

APLASTIC ANEMIA & MDS INTERNATIONAL FOUNDATION, INC.
NOTES TO THE FINANCIAL STATEMENTS
For the years ended December 31, 2022 and 2021

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GENERAL INFORMATION
(Continued)

Adoption of New Accounting Standards for Leases (Continued)

The lease classification affects both the pattern and presentation of expense recognized in the statements of activities, the categorization of assets and liabilities in the statements of financial position, and classification of cash flows in the statements of cash flows. Leases with a term of less than 12 months will not be recorded as the ROU asset and lease liability, and the payments will be recognized into profit or loss on a straight-line basis over the lease term.

The Foundation elected to adopt FASB ASC 842, *Leases*, by applying the optional transition method, which allows the Foundation to initially apply the new lease standard at the adoption date and recognize a cumulative effect adjustment to the opening balance of net assets in the period of adoption. As a result, the Foundation's reporting for leases in the prior year (2021) is presented in accordance with the prior historical accounting treatment.

The Foundation elected to adopt the package of practical expedients available under the transition guidance with the new standard. This package includes the following: relief from determination of lease contracts included in existing or expiring leases at the point of adoption, relief from having to reevaluate the classification of leases in effect at the point of adoption, and relief from reevaluation of existing leases that have initial direct costs associated with the execution of the lease contract. The Foundation also elected to adopt the practical expedient to use hindsight to determine the lease term and assess the impairment of the ROU assets.

The adoption of the new standards had no impact on net assets. As of January 1, 2022, the Foundation recorded an operating lease ROU asset, net of accumulated amortization, of \$411,613, an operating lease liability of \$473,856, and eliminated the deferred rent of \$62,243

Total lease cost consists of two components: amortization expense related to the write-off of the ROU assets and interest expense from lease liabilities. For operating leases, total lease cost is measured and recorded on a straight-line basis over the lease term. Lease liabilities are measured and recorded at the present value of future lease payments using a discount rate. Because the Foundation generally does not have access to the rate implicit in each lease, lease liabilities are measured using the risk-free rate as the discount rate. ROU assets are generally measured and recorded at the sum of the lease liability, any initial direct costs to consummate the lease, and any lease payments made on or before the commencement date.

APLASTIC ANEMIA & MDS INTERNATIONAL FOUNDATION, INC.
NOTES TO THE FINANCIAL STATEMENTS
For the years ended December 31, 2022 and 2021

NOTE 2 - CONCENTRATIONS AND RISKS

Concentration of Donors

For the year ended December 31, 2022, two donors accounted for 30% of the contributions and grant support and accounted for 66% of contributions and grants receivable. For the year ended December 31, 2021, two donors accounted for 25% of the contributions and grant support and 63% of contributions and grants receivable.

If a significant reduction in these donors should occur, it may have an effect on the Foundation's programs.

Concentration of Credit Risk

The Foundation's investments are exposed to various risks such as market conditions and credit/interest rate fluctuation. Due to the level of risk associated with such investments, and the level of uncertainty related to changes in the value of such investments, it is at least reasonably possible that changes in risks in the near term could materially affect investment balances and the amounts reported in the financial statements. The Finance Committee of the Board regularly monitors the Foundation's investment portfolio consistent with the Foundation's Investment Policy Guidelines and discusses the performance of the Foundation's investment portfolio with the Foundation's external investment advisors. Based on those discussions, the Finance Committee recommends changes in investment allocations, changes in managers or makes other recommendations to the Board to preserve the Foundation's liquidity and long-term investment stability. Investments in marketable securities with readily determinable fair values are reported at their fair values in the statements of financial position.

The Foundation maintains cash deposit and transaction accounts, along with investments, with financial institutions that may exceed insurable limits under the Federal Deposit Insurance Corporation (FDIC) and the Securities Investor Protection Corporation (SIPC). The Foundation has not experienced any credit losses on its cash and investments to date, as it relates to FDIC and SIPC insurance limits. Management assesses the financial condition of these financial institutions and believes that the risk of any credit loss is minimal.

NOTE 3 - INVESTMENTS

As of December 31, 2022 and 2021, investments at fair value consisted of the following:

	<u>2022</u>	<u>2021</u>
U.S. Treasury notes and bonds	\$ 187,192	\$ 57,651
Corporate bonds	192,957	137,922
Common stocks	530,646	620,580
Mutual funds	<u>509,534</u>	<u>797,625</u>
Total investments	<u>\$ 1,420,329</u>	<u>\$ 1,613,778</u>

APLASTIC ANEMIA & MDS INTERNATIONAL FOUNDATION, INC.
NOTES TO THE FINANCIAL STATEMENTS
For the years ended December 31, 2022 and 2021

NOTE 3 - INVESTMENTS (Continued)

For the years ended December 31, 2022 and 2021, net investment returns included the following:

	<u>2022</u>	<u>2021</u>
Interest and dividends	\$ 48,543	\$ 51,744
Unrealized gains (losses)	(193,251)	51,322
Realized gains (losses)	(12,232)	25,673
Less, management fees	<u>(16,080)</u>	<u>(15,746)</u>
Total investment returns, net	<u>\$ (173,020)</u>	<u>\$ 112,993</u>

NOTE 4 - CHARITABLE REMAINDER TRUST

The Foundation entered into an irrevocable life tenancy agreement in 2004 with an individual, whereby the Foundation will receive the individual's residence upon his death.

Under accounting principles generally accepted in the United States of America, the beneficial interest to the Foundation is measured at the present value of the estimated future cash flow to be received by the Foundation. The fair value of the property at December 31, 2004, which was determined by an independent appraisal performed in April 2005, was \$475,000.

The fair value was discounted to present value over an estimated life of 20 years, at a discount rate of 6%, and reported in the wills and change in fair value of trust revenue line item in the accompanying statements of activities. For the years ended December 31, 2022 and 2021, the present value adjustment increased the value of the Foundation's beneficial interest in the Charitable Remainder Trust by \$21,296 and \$20,092, respectively.

NOTE 5 - FAIR VALUE MEASUREMENTS

In accordance with FASB ASC 820, *Fair Value Measurement*, the Foundation has categorized its financial instruments, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure the financial instruments fall within different levels of hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

Investments recorded in the statements of financial position are categorized based on the inputs to valuation techniques as follows:

Level 1. These are investments where values are based on unadjusted quoted prices for identical assets in an active market that the Foundation has the ability to access.

APLASTIC ANEMIA & MDS INTERNATIONAL FOUNDATION, INC.
NOTES TO THE FINANCIAL STATEMENTS
For the years ended December 31, 2022 and 2021

NOTE 5 - FAIR VALUE MEASUREMENTS (Continued)

Level 2. These are investments where values are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-based valuation techniques that utilize inputs that are observable either directly or indirectly for substantially the full term of the investments.

Level 3. These are investments where inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The following is a description of the valuation methodology used for investments measured at fair value. There have been no changes in the methodologies used as of December 31, 2022 and 2021:

- U.S. Treasury notes and bonds - Valued at the closing price reported on the active market in which the individual securities are traded.
- Corporate bonds - generally valued at the most recent price of the equivalent quoted price for such securities. Debt securities, which are actively traded, are classified within Level 1 of the valuation hierarchy.
- Common stocks - Valued at the closing price reported on the active market in which the individual securities are traded.
- Mutual funds - Valued at the daily closing price as reported by the fund. Mutual funds held by the Foundation are open-end mutual funds that are registered with the SEC. These funds are required to publish their daily net asset value and to transact at that price.
- Charitable Remainder Trust - Valued at the estimated present value of the appraised value of a life tenancy agreement.

As of December 31, 2022 and 2021, the tables below present the fair value of the investments and Charitable Remainder Trust by level within the hierarchy.

	December 31, 2022			
	Level 1	Level 2	Level 3	Total
U.S. Treasury notes and bonds	\$ 187,192	\$ -	\$ -	\$ 187,192
Corporate bonds	-	192,957	-	192,957
Common stocks	530,646	-	-	530,646
Mutual funds	<u>509,534</u>	<u>-</u>	<u>-</u>	<u>509,534</u>
Total investments	1,227,372	192,957	-	1,420,329
Charitable Remainder Trust	<u>-</u>	<u>-</u>	<u>376,244</u>	<u>376,244</u>
Total investments and Trust	<u>\$ 1,227,372</u>	<u>\$ 192,957</u>	<u>\$ 376,244</u>	<u>\$ 1,796,573</u>

APLASTIC ANEMIA & MDS INTERNATIONAL FOUNDATION, INC.
NOTES TO THE FINANCIAL STATEMENTS
For the years ended December 31, 2022 and 2021

NOTE 5 - FAIR VALUE MEASUREMENTS (Continued)

	December 31, 2021			
	Level 1	Level 2	Level 3	Total
U.S. Treasury notes and bonds	\$ 57,651	\$ -	\$ -	\$ 57,651
Corporate bonds	-	137,922	-	137,922
Common stocks	620,580	-	-	620,580
Mutual funds	<u>797,625</u>	<u>-</u>	<u>-</u>	<u>797,625</u>
Total investments	1,475,856	137,922	-	1,613,778
Charitable Remainder Trust	<u>-</u>	<u>-</u>	<u>354,948</u>	<u>354,948</u>
Total investments and Trust	<u>\$ 1,475,856</u>	<u>\$ 137,922</u>	<u>\$ 354,948</u>	<u>\$ 1,968,726</u>

There were no transfers between levels in the fair value hierarchy during the years ended December 31, 2022 and 2021. Transfers between levels are recorded at the end of the reporting period, if applicable.

The following table provides a summary of changes in present value of the Foundation's Charitable Remainder Trust asset for the years ended December 31, 2022 and 2021:

	<u>2022</u>	<u>2021</u>
Balance, beginning of year	\$ 354,948	\$ 334,856
Present value adjustment	<u>21,296</u>	<u>20,092</u>
Balance, end of year	<u>\$ 376,244</u>	<u>\$ 354,948</u>

The change in present value adjustment has been reported in the statements of activities in the revenue with donor restrictions.

APLASTIC ANEMIA & MDS INTERNATIONAL FOUNDATION, INC.
NOTES TO THE FINANCIAL STATEMENTS
For the years ended December 31, 2022 and 2021

NOTE 6 - BOARD-DESIGNATED NET ASSETS WITHOUT DONOR RESTRICTIONS

The Board of Directors has designated funds to be used to support grants given for research in finding treatments for various bone marrow failure diseases. Changes in the Board-designated net assets for the years ended December 31, 2022 and 2021 are as follows:

	<u>2022</u>	<u>2021</u>
Board-designated net assets, beginning of the year	\$ 150,000	\$ 120,000
Additions	-	60,000
Releases	<u>(60,000)</u>	<u>(30,000)</u>
Board designated net assets, end of the year	<u>\$ 90,000</u>	<u>\$ 150,000</u>

NOTE 7 - NET ASSETS WITH DONOR RESTRICTIONS

The Foundation's net assets with donor restrictions consisted of the following as of December 31, 2022 and 2021:

	<u>2022</u>	<u>2021</u>
Subject to time restriction:		
Charitable Remainder Trust	<u>\$ 376,244</u>	<u>\$ 354,948</u>
Subject to expenditure for specified purposes:		
Awareness	17,500	45,000
Health professional education programs	-	35,000
Patient educational programs and conferences	120,844	315,067
Research	<u>469,141</u>	<u>457,900</u>
	<u>607,485</u>	<u>852,967</u>
Total net assets with donor restrictions	<u>\$ 983,729</u>	<u>\$ 1,207,915</u>

APLASTIC ANEMIA & MDS INTERNATIONAL FOUNDATION, INC.
NOTES TO THE FINANCIAL STATEMENTS
For the years ended December 31, 2022 and 2021

NOTE 7 - NET ASSETS WITH DONOR RESTRICTIONS (Continued)

The following net assets with donor restrictions were released from donor restrictions, for the years ended December 31, 2022 and 2021 by incurring expenses, which satisfied the restricted purposes specified by the donors:

	<u>2022</u>	<u>2021</u>
Awareness	\$ 160,074	\$ 230,600
Health professional education programs	410,239	536,961
Patient educational programs and conferences	1,558,691	1,469,430
Research	<u>144,415</u>	<u>129,195</u>
Total net assets with donor restrictions	<u>\$ 2,273,419</u>	<u>\$ 2,366,186</u>

NOTE 8 - PAYCHECK PROTECTION PROGRAM (PPP) GRANT REVENUE

During the year ended December 31, 2021, the Foundation entered into a U.S. Small Business Administration (SBA) PPP loan in the principal amount of \$182,336 (PPP2 Loan). The loan was uncollateralized and fully guaranteed by the Federal Government. The Foundation was eligible for loan forgiveness of up to 100% of the loan, upon meeting certain requirements such as maintaining employment levels during an eight-week or twenty-four-week period and using the funds (at stipulated percentages) for certain payroll and expenses. The Foundation initially recorded the loan as a refundable advance and subsequently recognized grant revenue in accordance with guidance for conditional contributions under FASB ASC 958-605; that is, the Foundation recorded the PPP loans as a grant once the measurable performance or other barrier and right of return of the PPP loans no longer existed. The Foundation has recognized the full amount of the loans as Paycheck Protection Program grant revenue for the year ended December 31, 2021 in the statement of activities. The PPP2 Loan was forgiven on December 27, 2021.

According to the rules of the SBA governing the PPP Loan Program, the Foundation is required to retain documentation for six years after the date of the refundable advance is forgiven or repaid in full and permit authorized representatives of the SBA to access such files upon request.

NOTE 9 - PENSION PLAN

The Foundation established and maintains an independent 403(b) retirement plan (the Plan). The Plan is available to full-time and part-time employees who are at least 21 years old. The Foundation currently matches 100% of employee deferral contributions, up to 4% of eligible compensation. The Foundation contributed \$19,953 and \$20,725 for the years ended December 31, 2022 and 2021, respectively, which is included in employee benefits expense in the accompanying statements of functional expenses.

APLASTIC ANEMIA & MDS INTERNATIONAL FOUNDATION, INC.
NOTES TO THE FINANCIAL STATEMENTS
For the years ended December 31, 2022 and 2021

NOTE 10 - OFFICE LEASE

The Foundation entered into a 92-month office space lease agreement beginning in October 2016. Base rent is \$175,707 per year, plus a proportionate share of expenses. Beginning with the third year of the lease, base rent increases by a factor of 2.5% each year. Under the terms of the lease, the landlord granted the Foundation an abatement of base rent and its share of expenses for the first eight months after the commencement date. The lease is classified as an operating lease and expires in May 2024.

An amendment to the lease was effective April 3, 2019. The Foundation received a partial deferral of the base rent obligations. The Foundation was permitted to defer up to 50% of base rents due under the lease during the period of April 1, 2019 through December 31, 2019 or the deferral period termination date.

As of December 31, 2022, the right-of-use asset related to the operating lease was as follows:

Right-of-use asset - operating:

Cost	\$ 411,613
Less: accumulated amortization	<u>(168,884)</u>
Right-of-use asset, net	<u>\$ 242,729</u>

As of December 31, 2022, the liability related to the operating lease was as follows:

Liability:

Lease liability, operating - current portion	\$ 181,144
Lease liability, operating - non-current portion	<u>101,575</u>
Lease liability - operating	<u>\$ 282,719</u>

The weighted-average remaining lease term for the operating lease as of December 31, 2022 was 1.42 years. The weighted-average discount rate for the operating lease as of December 31, 2022 was 1.04%.

Future minimum payments are as follows for the office lease for the years ending December 31:

2023	\$ 200,039
2024	<u>84,903</u>
Total undiscounted cash flows	284,942
Less: present value discount	<u>(2,223)</u>
Total	<u>\$ 282,719</u>

APLASTIC ANEMIA & MDS INTERNATIONAL FOUNDATION, INC.
NOTES TO THE FINANCIAL STATEMENTS
For the years ended December 31, 2022 and 2021

NOTE 10 - OFFICE LEASE (Continued)

The Foundation records occupancy expense on the straight-line method over the term of the lease and includes cash paid for rent plus amortization of the operating lease liability. For the years ended December 31, 2022 and 2021, occupancy expense totaled \$188,203 and \$178,912, respectively.

NOTE 11 - LIQUIDITY AND AVAILABILITY

Financial assets available for use within one year of the statement of financial position were comprised of the following at December 31, 2022 and 2021:

	<u>2022</u>	<u>2021</u>
Cash and cash equivalents	\$ 2,938,625	\$ 2,774,248
Contributions and grants receivable	686,175	367,344
Investments	<u>1,420,329</u>	<u>1,613,778</u>
Total financial assets	5,045,129	4,755,370
Less: financial assets unavailable for expenditure within one year due to:		
Net assets with donor restrictions for special purposes	(349,141)	(367,900)
Board-designated net assets	<u>(90,000)</u>	<u>(90,000)</u>
Financial assets available to meet cash needs for general expenditure within one year	<u>\$ 4,605,988</u>	<u>\$ 4,297,470</u>

The Foundation has a policy to structure their financial assets to be available and liquid as their obligations become due.

The Foundation has certain donor-restricted net assets that are available for general expenditures within one year of the statement of financial position date, because the restrictions on the net assets are expected to be met by conducting the normal activities of the programs in the coming year. Accordingly, the related resources have been included in the quantitative information detailing the financial assets available to meet general expenditures within one year. Additionally, they have a Board-designated reserve which they may draw upon, pending Board approval.

NOTE 12 - SUBSEQUENT EVENTS

In preparing these financial statements, the Foundation has evaluated events and transactions for potential recognition or disclosure through June 2, 2023, which is the date the financial statements were available to be issued. There were no subsequent events noted that required adjustments to, or disclosure in, these financial statements.